A carregar...
Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety conce...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7919188/ https://ncbi.nlm.nih.gov/pubmed/33658933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.589146 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|